Table 2. Summary of marker prevalence.
| Marker | N | N (%) | Median (min–max) |
|---|---|---|---|
| p16 |
90 |
|
|
| Positive | 56 (62%) | ||
| Negative |
|
34 (38%) |
|
| p16 (Oropharynx) |
64 |
|
|
| Positive | 50 (78%) | ||
| Negative |
|
14 (22%) |
|
| p16 (Non-oropharynx) |
26 |
|
|
| Positive | 6 (23%) | ||
| Negative |
|
20 (77%) |
|
| ERCC1 (FL297) |
88 |
|
2.25 (0.1–3.0) |
| Decreaseda | 12 (14%) | ||
| Normala | 36 (41%) | ||
| Increaseda |
|
40 (45%) |
|
| ERCC1 (4F9) |
88 |
|
2.5 (0.1–3.0) |
| Decreaseda | 14 (16%) | ||
| Normala | 26 (30%) | ||
| Increaseda |
|
48 (54%) |
|
| ERCC1 (8F1) |
90 |
|
2.25 (0.1–3.0) |
| Decreaseda | 30 (33%) | ||
| Normala | 18 (20%) | ||
| Increaseda | 42 (47%) |
Normal: 1.5 <H-score<2.5.
Increased: H-score ⩾2.5.
a
Decreased: H-score ⩽1.5.